Egnach, March 11, 2026 – The health platform tinniwell is preparing to launch a scientifically oriented testing phase for its digital application designed to support people suffering from tinnitus. The live test of the app is scheduled to begin next month and will be conducted within a structured test environment in order to systematically observe usage, user acceptance, and potential effects in everyday life.

 Tinnitus affects millions of people across Europe and represents a significant reduction in quality of life for many sufferers. In addition to traditional medical treatment approaches, digital support programs are gaining increasing importance. Such applications can help users, for example, with symptom self-monitoring, relaxation exercises, or training programs based on behavioral therapy concepts.

 With the newly established test environment, tinniwell aims to evaluate the practical use of its digital solution under realistic conditions. During the pilot phase, initial users will use the app in their daily lives while structured feedback will be collected regarding usability, usage patterns, and potential improvements.

 “The establishment of a controlled test environment is an important step in the development of digital health solutions,” explains Anke Rauterkus, CEO of Resaphene. “Our goal is to observe the application under conditions that are as close as possible to real-life use and to generate scientifically sound insights into the usage and effects of digital support programs for tinnitus.”

 Digital health applications are increasingly being considered within the healthcare sector as a complement to traditional therapeutic approaches. Structured test environments allow developers to validate applications prior to broader market introduction and further develop them based on real-world usage data.

 After completion of the testing phase, Resaphene plans to apply for inclusion as a Digital Health Application (DiGA) in Germany based on the data obtained.

++ Contact for questions:

Resaphene Suisse AG

Mrs. Anke Rauterkus (Chief Executive Officer)

Bahnhofplatz 5

9322 Egnach

Switzerland

T. +41 71 510 07 24

a.rauterkus@resaphene.ch